Veterinary Medicines

Vanguard Plus 5/L EU, Lyofilizát a rozpouštědlo pro injekční suspenzi

Authorised
  • Canine distemper virus, strain N-CDV, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
Download as PDF

Product identification

Medicine name:
Vanguard Plus 5/L EU, Lyofilizát a rozpouštědlo pro injekční suspenzi
Active substance:
  • Canine distemper virus, strain N-CDV, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain N-CDV, Live
    5.50
    log10 cell culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan, Live
    5.20
    log10 cell culture infective dose 50
    /
    1.00
    Dose
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    8.00
    log10 cell culture infective dose 50
    /
    1.00
    Dose
  • Canine parvovirus, strain NL-35-D, Live
    8.50
    log10 cell culture infective dose 50
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    740.00
    relative potency
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    915.00
    relative potency
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Available in:
  • Czechia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Ceska Republika s.r.o.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
  • 97/668/92-S/C/02
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 16/01/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 16/01/2023
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 16/01/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."